Organon & Co (OGN)
18.07
-0.71
(-3.78%)
USD |
NYSE |
Nov 01, 16:00
18.02
-0.05
(-0.28%)
After-Hours: 20:00
Organon Enterprise Value: 12.64B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 12.64B |
| October 31, 2024 | 12.82B |
| October 30, 2024 | 12.60B |
| October 29, 2024 | 12.58B |
| October 28, 2024 | 12.48B |
| October 25, 2024 | 12.41B |
| October 24, 2024 | 12.42B |
| October 23, 2024 | 12.42B |
| October 22, 2024 | 12.45B |
| October 21, 2024 | 12.48B |
| October 18, 2024 | 12.52B |
| October 17, 2024 | 12.53B |
| October 16, 2024 | 12.61B |
| October 15, 2024 | 12.63B |
| October 14, 2024 | 12.65B |
| October 11, 2024 | 12.62B |
| October 10, 2024 | 12.62B |
| October 09, 2024 | 12.63B |
| October 08, 2024 | 12.65B |
| October 07, 2024 | 12.65B |
| October 04, 2024 | 12.70B |
| October 03, 2024 | 12.69B |
| October 02, 2024 | 12.77B |
| October 01, 2024 | 12.84B |
| September 30, 2024 | 12.91B |
| Date | Value |
|---|---|
| September 27, 2024 | 12.89B |
| September 26, 2024 | 12.89B |
| September 25, 2024 | 12.85B |
| September 24, 2024 | 13.01B |
| September 23, 2024 | 13.03B |
| September 20, 2024 | 12.97B |
| September 19, 2024 | 13.15B |
| September 18, 2024 | 13.09B |
| September 17, 2024 | 13.24B |
| September 16, 2024 | 13.33B |
| September 13, 2024 | 13.22B |
| September 12, 2024 | 13.18B |
| September 11, 2024 | 13.14B |
| September 10, 2024 | 13.12B |
| September 09, 2024 | 13.15B |
| September 06, 2024 | 13.23B |
| September 05, 2024 | 13.45B |
| September 04, 2024 | 13.67B |
| September 03, 2024 | 13.64B |
| August 30, 2024 | 13.71B |
| August 29, 2024 | 13.70B |
| August 28, 2024 | 13.74B |
| August 27, 2024 | 13.72B |
| August 26, 2024 | 13.88B |
| August 23, 2024 | 13.71B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
8.592B
Minimum
Jun 09 2021
18.38B
Maximum
Mar 02 2022
14.50B
Average
14.27B
Median
Nov 09 2022
Enterprise Value Benchmarks
| Eli Lilly and Co | 805.11B |
| Biomarin Pharmaceutical Inc | 12.36B |
| Cassava Sciences Inc | 1.050B |
| Ligand Pharmaceuticals Inc | 1.783B |
| TG Therapeutics Inc | 4.050B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 359.00M |
| Revenue (Quarterly) | 1.582B |
| Total Expenses (Quarterly) | 1.192B |
| EPS Diluted (Quarterly) | 1.38 |
| Gross Profit Margin (Quarterly) | 58.34% |
| Profit Margin (Quarterly) | 22.69% |
| Earnings Yield | 27.89% |
| Operating Earnings Yield | 32.18% |
| Normalized Earnings Yield | 31.18 |